

Kirill Lotonin^{1,2,3}, Francisco Brito^{1,2}, Kemal Mehinagic^{1,2}, Obdulio García-Nicolás^{1,2}, Matthias Liniger^{1,2}, Noelle Donzé^{1,2}, Sylvie Python^{1,2}, Stephanie Talker^{1,2}, Nicolas Ruggli^{1,2}, Charaf Benarafa^{1,2}, Artur Summerfield^{1,2}


¹Institute of Virology and Immunology IVI, Mittelhäusern, Switzerland

²Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland






³Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland

Introduction

Live attenuated vaccines (LAVs) have shown promise in providing protection against ASFV, but their broader application is limited by safety concerns and an incomplete understanding of the immune mechanisms underlying protection. In this study, we used an established model with two groups of pigs differing in baseline immunological status (farm and specific pathogen-free, or SPF) to dissect protective and detrimental immune responses following immunization with the attenuated Estonia 2014 strain and subsequent challenge with the pathogenic Armenia 2008 strain. By applying a systems immunology approach, we correlated immunological data, including serum cytokines, T-cell responses, and blood transcription modules (BTMs), with clinical outcomes of the challenge.



protection lack of protection



Conclusions

- Key innate correlates of protection included early and sustained IFN- α response, activation of antigen presentation BTMs, and controlled IL-8 levels during immunization.
- Lower baseline immune activation was linked to increased protective immunity.
- Adaptive correlates included cell cycle, plasma cell, and T-cell BTM responses lasting until day 15 post-immunization.
- Consequently, an effective response from ASFV-specific T_h cells, together with sustained levels of IL-1 β , predicted protection.
- After the challenge, an early IFN- α response, along with low levels of pro-inflammatory cytokines and a strong induction of memory T_h and T_c cells, correlated with improved clinical outcomes.
- The model provides a framework for assessing efficacy of LAV vaccine candidates against ASFV and should be further validated in a farm pig setting.